7.10.2024 12:08:46 CEST | Monsenso |
Investor Nyheder
En kognitiv adfærdsterapi (CBT) app, baseret på Monsenso’s platform, har vist sig at forhindre stigninger i depression hos unge mennesker, der er i høj risiko. Appen vurderes at kunne implementeres som en omkostningseffektiv offentlig mental sundhedsforanstaltning.
Globalt vokser bekymringen over de høje og støt stigende forekomster af angst og depression hos unge. Der er brug for effektive og skalerbare måder at forebygge dårligt mentalt helbred i denne gruppe på, og digitale værktøjer såsom mobilapps er blevet foreslået som en del af løsningen.
Selvom der er nye beviser for, at apps til mental sundhed er effektive til behandling af angst og depression, er dette projekt ledet af University of Exeter det første, der grundigt tester en app til mental sundhed i så stor skala i fire lande. To forbundne forskningsartikler offentliggjort den 4. oktober i Lancet Digital Health rapporterer resultaterne af ECoWeB-PREVENT og ECoWeB-PROMOTE forsøgene, som kørte sideløbende i det fire-årige studie finansieret af Horizon 2020. Kritisk set viste disse forsøg, at en CBT-selvhjælps app baseret på Monsenso’s platform kan beskytte sårbare unge mod depression.
Professor Ed Watkins fra University of Exeter ledede projektet og sagde: “For unge mennesker med forhøjet risiko tyder vores resultater på, at CBT-appen har en forebyggende effekt på depression og kan have en fordel for folkesundheden. Deltagernes livskvalitetsmål var bedre, og deres rapporterede arbejde og sociale funktion var bedre.
»Vi fandt dog også ud af, at det er svært at lave forbedringer hos unge, som grundlæggende har det okay. Vores resultater tilføjer beviserne for, at forebyggelse af depression virker bedst, når vi identificerer og udvælger personer, der er mere udsatte i stedet for at tage en mere universel tilgang. Denne identifikation kan ske ved en online selvscreeningsproces eller gennem professionel henvisning.”
CEO Thomas Lethenborg fra Monsenso: “Vi er glade for studiets resultater og ser stort forretningspotentiale baseret på det. Det viser, at Monsensos platform kan bruges til at levere omkostningseffektive, selvhjælpsbaserede forebyggelsesindsatser i stor skala, og at den muliggør effektive, internationale decentraliserede forsøg, hvor borgeres egne data kontinuerligt indsamles til gavn for forskningen”.
Målet med projektet til EUR 4 millioner var at teste virkningerne af mobilapps til at forebygge depression og fremme mentalt velvære for unge i alderen 16 til 22. I en af de største undersøgelser af sin art deltog 3.700 unge på tværs af Storbritannien, Tyskland, Belgien og Spanien og blev fordelt i to studier baseret på deres følelsesmæssige kompetencer ved starten af undersøgelsen. Det resulterede i, at 1.200 unge mennesker med reduceret emotionel kompetencescore, der giver øget risiko for depression, såsom øget bekymring og overtænkning, gik ind i et forsøg med fokus på forebyggelse, mens 2.500 uden en sådan risiko gik i det andet forsøg med fokus på at fremme velvære.
Disse to grupper blev derefter randomiseret til tre forskellige apps udviklet af projektet baseret på Monsenso’s platform. Der var en selvovervågnings-app, hvor deltagerne kunne rapportere deres følelser hver dag, en selvhjælps-app, der gav personlig træning i emotionelle kompetencer, og en selvhjælps-app baseret på CBT-principper. Deltagerne blev derefter fulgt op efter tre måneder og 12 måneder for at se, hvordan deres trivsel og depressionssymptomer ændrede sig.
Forsøgene viste, at CBT-appen forhindrede en stigning i depression i forhold til selvmonitorering i gruppen med øget risiko, men at der ikke var nogen forskel mellem nogen af interventionerne i deres virkning for gruppen med lavere risiko.
Professor Ed Watkins sagde: “Vores resultater tyder på, at selv når unge brugte selvhjælpsappen et par gange, var der en lille, men meningsfuld fordel. Fordi appen er skalerbar til et stort antal mennesker på en omkostningseffektiv måde, har disse effekter potentiel værdi som en folkesundhedsintervention inden for en bredere portefølje af digitale og personlige ydelser og interventioner. Næste trin er at identificere de aktive elementer i appen, der var gavnlige og at forbedre engagementet og den løbende brug af disse elementer.”
Projektet involverede 13 forskellige partnere, herunder to kommercielle virksomheder – danske Monsenso, som udviklede de nævnte app baseret på sin digitale sundhedsplatform og det tyske stemmeanalysefirma auDERING. Exeter Universitet (Storbritannien), LMU München (Tyskland), Gent Universitet (Belgien) og Universitat Jaume I (Spanien) var de vigtigste behandlingsudviklings- og forsøgssteder. Den kvalitative analyse blev ledet af Oxford Universitet.
Undersøgelserne har titlerne ‘Emotionel kompetence-selvhjælps-app versus kognitiv-adfærdsmæssig selvhjælps-app versus selvmonitorerings-app for at forebygge depression hos unge voksne med forhøjet risiko (ECoWeB PREVENT): et internationalt, multicenter, parallelt, åbent, randomiseret kontrolleret forsøg’. og ‘Emotionel kompetence-selvhjælps-app til mobiltelefoner versus kognitiv adfærdsbaseret selvhjælps-app versus selvmonitorerings-app til fremme af mental trivsel hos raske unge voksne (ECoWeB PROMOTE): et internationalt, multicenter, parallelt, åbent, randomiseret kontrolleret forsøg’ og begge er publiceret i Lancet Digital Health. Projektet blev støttet af European Union Horizon 2020 Personalized Medicine SC1-PM-07–2017 tilskudsaftale 754657.
For yderligere information:
University of Exeter:Pressekontor+44 (0)1392 722405 eller
Thomas Lethenborg, CEOTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning til brug for decentaliserede forsøg, patientmonitorering og behandlingsunderstøttelse. Vores mission er at bidrage til bedre sundhed til flere personer og lavere omkostninger ved at understøtte behandling digitalt og bedre udnytte patienters egne data. Vores løsning bidrager til optimering af behandlingen og giver et detaljeret overblik over patienters sundhed via indsamling af data om deres tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig intervention. Vi samarbejder med sundhedsvæsenet, medicinalindustrien og forskningsinstitutioner verden over i vores forsøg på at levere løsninger som passer ind i patienters og sundhedsprofessionelles hverdag. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
7.10.2024 12:08:46 CEST | Monsenso |
Investor News
A cognitive behavioural therapy (CBT) app, based on Monsenso’s digital health platform, has been found to significantly prevent increases in depression in young people who are at high risk – and could be implemented as a cost-effective, large-scale public mental health measure.
Globally, concern is growing about the high and steadily increasing rates of anxiety and depression in young people. Effective and scalable ways of preventing poor mental health in this group are needed, and digital tools such as mobile apps have been proposed as part of the solution.
Whilst there is emerging evidence for mental health apps being effective in treating anxiety and depression, the EcoWeB project led by the University of Exeter is the first to rigorously test a mental health app on such a large scale across four countries. Two linked papers published on Oct 4 in Lancet Digital Health report the results of the ECoWeB-PREVENT and ECoWeB-PROMOTE trials, which ran concurrently in the four-year study funded by Horizon 2020. Critically, these studies found that a CBT self-help app based on Monsenso’s digital health platform can protect vulnerable young people against depression.
Professor Ed Watkins from the University of Exeter led the project and said: “For young people with elevated risk, our findings suggest the CBT app does have a preventative effect on depression and could have a public health benefit. Participants’ quality-of-life measures were better, and their reported work and social functioning was better.
“However, we also found that it’s hard to make improvements in young people who are basically doing okay. Our findings add to the evidence that prevention for depression works best when we identify and select individuals who are more at risk, rather than take a more universal approach. This identification could be done by an online self-screening process or through professional referral.”
CEO Thomas Lethenborg at Monsenso said: “We are happy with the outcomes of this study and see great potential for our platform based on this. It shows that our platform can be used to deliver cost-effective guidance and interventions at scale and that it can be used to enable large-scale, international decentralised trials collecting continuous real-world data from participants.”
The aim of the EUR 4-million project was to test the effects of mobile apps in preventing depression and promoting mental well-being for young people aged 16 to 22. In one of the largest studies of its kind, 3,700 young people took part across the UK, Germany, Belgium, and Spain and were allocated into two trials based on their emotional competence abilities at the start of the study. That resulted in 1,200 young people with reduced emotional competency scores that confer increased risk for depression such as increased worry and overthinking going into one trial focused on prevention, whilst 2,500 without such risk went into the other trial focused on wellbeing promotion.
Those two groups were then randomised in equal numbers to three different apps developed by the project based on Monsenso’s platform. There was a self-monitoring app where people can report their emotions every day, a self-help app that provided personalised training in emotional competence skills, and a self-help app based on CBT principles. Participants were then followed up at three months and 12 months to see how their wellbeing and depression symptoms changed.
The trials found the CBT app prevented an increase in depression, relative to self-monitoring in the higher risk sample, but that there was no difference between any of the interventions in their effects for the lower risk sample.
Professor Ed Watkins at University of Exeter said: “Our results suggest that even when young people used the self-help app just a few times, there was a small but meaningful benefit. Because the app is scalable to large numbers of people in a cost-effective way, these effects have potential value as a public health intervention, within a broader portfolio of digital and in-person services and interventions. Next steps are to identify the active ingredients of the app that were beneficial and to improve engagement and ongoing use of these elements.”
The project involved 13 different partners, including two commercial companies – digital health platform provider Monsenso and German voice analysis company audEERING. The University of Exeter (UK), LMU Munich (Germany), Ghent University (Belgium), and Universitat Jaume I (Spain), were the main treatment development and trial sites. Meanwhile, the University of Oxford led on the qualitative analysis.
The studies are titled ‘Emotional competence self-help app versus cognitive-behavioural self-help app versus self-monitoring app to prevent depression in young adults with elevated risk (ECoWeB PREVENT): an international, multicentre, parallel, open-label, randomised controlled trial’ and ‘Emotional competence self-help mobile phone app versus cognitive behavioural self-help app versus self-monitoring app to promote mental wellbeing in healthy young adults (ECoWeB PROMOTE): an international, multicentre, parallel, open-label, randomised controlled trial’, and both are published in Lancet Digital Health. This work was supported by European Union Horizon 2020 Personalised Medicine SC1-PM-07–2017 grant agreement 754657.
For further information:
University of Exeter Press Office +44 (0)1392 722405 or 722062 pressoffice@exeter.ac.uk
Monsenso A/SThomas Lethenborg, CEOTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
